Fulgent Pharma is a clinical stage pharmaceutical company focused on developing and commercializing innovative cancer therapeutics. Our pipeline includes both improved chemotherapy drugs through nanoencapsulation and innovative new drug candidates, all of which are targeted at treating a broad range of cancers, including breast, lung, ovarian, colon, and pancreatic cancer.
The company's lead asset is FID-007, a nanoencapsulated paclitaxel with improved drug efficacy and decreased toxicity, which is currently being tested in clinical trials.
Nanoencapsulation of poorly soluble drugs with non-toxic, non-immunogenic, and biocompatible polymers has successfully enhanced drug delivery, safety, and effectiveness. Fulgent Pharma combines its patented nanoencapsulation technology with both established and early-discovery anti-cancer drugs to create new therapies with lower toxicity, targeted delivery, and enhanced tumor reduction.
Targeted therapies for primary human myelodysplastic syndrome (MDS) progenitors and hematopoietic stem cells (HSC).
Small-molecule based checkpoint inhibitors. Enhancing nano-biotherapeutics with next generation sequencing.Learn More